Form 4: NeuroBo Pharmaceuticals CFO Receives Stock Grant

Marshall H. Woodworth, CFO of NeuroBo Pharmaceuticals, was granted 33,496 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

Summary

• On March 1, 2024, Marshall H. Woodworth, the Chief Financial Officer of NeuroBo Pharmaceuticals, received a grant of 33,496 restricted stock units (RSUs).
• These RSUs were issued under the Issuer's 2022 Equity Incentive Plan.
• The RSUs vest in three tranches: 30% on the first anniversary of the grant date, 30% on the second anniversary, and the remaining 40% in equal monthly installments over the 12 months following the second anniversary.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs aligns the CFO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The vesting schedule of the RSUs extends over three years, suggesting a focus on long-term performance and retention of the CFO.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to attract and retain key executives, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Equity compensation for CFOs in the pharmaceutical industry varies widely based on company size, stage of development, and performance.
• Comparing the size and vesting schedule of this RSU grant to those of CFOs at similar-stage biotech companies would provide a benchmark for assessing its competitiveness.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics also use equity grants as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the CFO to drive long-term value.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates